Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CASR | P41180 | 2/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1469953 | 1.00 | CYP3A4 (0.61) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL8366747 | 1.00 | CYP3A4 (0.61) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL3881699 | 0.83 | CYP3A4 (0.76) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL3881700 | 0.83 | CYP3A4 (0.76) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL5471668 | 0.83 | CYP3A4 (0.76) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL24406703 | 0.83 | CYP3A4 (0.76) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL12747746 | 0.82 | ACACB (0.53) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL12964248 | 0.82 | CYP3A4 (0.68) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL12964253 | 0.82 | CYP3A4 (0.68) | CYP3A4CASRCHRM2HTR1AADRA2A | |
| SCHEMBL172559 | 0.82 | CYP3A4 (0.68) | CYP3A4CASRCHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136552-A1 | ANTAGONISTS OF CAV 2.3 | LARIO THERAPEUTICS LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| EP-4436664-A1 | ANTAGONISTS OF CAV 2.3 | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| CN-117327050-A | Bimetal synergistic promotion system and application thereof in asymmetric synthesis of (S, S) -TBAJ-587 | 上海交通大学 | 2024-01-02 | — | — | CN | disclosed |
| WO-2023094828-A1 | ANTAGONISTS OF CAV 2.3 | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094828-A1 | ANTAGONISTS OF CAV 2.3 | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| US-11174256-B2 | Imidazopyridine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2021101919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021074778-A1 | AN INDUSTRIAL PROCESS FOR RESOLUTION OF CHLOCYPHOS | HIKAL LIMITED (IN) | 2021-04-22 | — | — | WO | disclosed |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-9938275-B2 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| WO-2011054845-A1 | BENZODIAZEPINE BROMODOMAIN INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-7928135-B2 | Benzene, pyridine, and pyridazine derivatives | SERENEX, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20110034529-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-7645741-B2 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | AEGERA THERAPEUTICS, INC. | 2010-01-12 | — | — | US | disclosed |
| US-20090163493-A9 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2009-06-25 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | PHARMASCIENCE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2008-04-24 | — | — | US | disclosed |
| EP-0711278-A1 | 2-(2-HYDROXYPHENYL)-5-(N-PHENYLMETHYL-AMINOMETHYL)-PYRROLES AS ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995004037-A1 | 2-(2-HYDROXYPHENYL)-5-(N-PHENYLMETHYL-AMINOMETHYL)-PYRROLES AS ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163493-A9 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | HSP90AA1, HSP90AB1, HSPA4 | CYP3A4 1143/4885CASR 4777/4885CHRM2 4483/4885 |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | HSP90AA1, HSP90AB1, HSPA4 | CYP3A4 1143/4885CASR 4777/4885CHRM2 4483/4885 |
| US-11174256-B2 | Imidazopyridine derivatives | TPMT, IRAK4, CFTR | CYP3A4 48/4885CASR 4225/4885CHRM2 1595/4885 |
| US-20110034529-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | CYP3A4 45/4885CASR 3308/4885CHRM2 284/4885 |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | BIRC5, XIAP, BAX | CYP3A4 4214/4885CASR 4363/4885CHRM2 3940/4885 |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | TPMT, IRAK4, CFTR | CYP3A4 48/4885CASR 4225/4885CHRM2 1595/4885 |
| US-20250136552-A1 | ANTAGONISTS OF CAV 2.3 | CACNA1E, CACNA1A, CACNA1S | CYP3A4 2976/4885CASR 190/4885CHRM2 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.